publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
much
larger
studi
would
necessari
show
import
differ
mortal
despit
similar
age
rang
pack
cell
volum
admiss
parasit
count
moder
sever
malaria
group
drug
produc
rapid
parasit
clearanc
former
latter
find
suggest
either
reduc
splenic
clearanc
function
larger
biomass
sequest
parasit
sever
absorpt
disposit
indic
chloroquin
similar
uncompl
sever
pharmacokinet
factor
would
therefor
explain
differ
parasitis
erythrocyt
larg
ring
form
remov
circul
drug
treatment
fulli
understood
mechan
may
distinct
abil
antimalari
drug
inhibit
kill
matur
parasit
sequest
microcircul
vital
studi
done
chloroquin
highli
effect
treatment
falciparum
malaria
gambia
howev
resist
develop
rapidli
parasit
clearanc
measur
longer
rl
resist
seen
half
patient
admit
studi
site
unpublish
highgrad
resist
soon
preclud
use
chloroquin
sever
malaria
treatment
need
urgent
artemesinin
compound
promis
howev
evid
yet
save
live
quinin
chloroquin
given
appropri
dose
issu
resolv
satisfactorili
larg
compar
studi
mortal
endpoint
thank
nurs
medic
staff
royal
victoria
pp
randomis
compar
studi
artemesinin
qinghaosu
suppositori
oral
quinin
acut
falciparum
malaria
tran
r
soc
trop
med
hyg
pe
myint
tin
shwe
efficaci
artemeth
qinghaosu
plasmodium
falciparum
p
vivax
burma
se
asian
j
trop
med
much
larger
studi
would
necessari
show
import
differ
mortal
despit
similar
age
rang
pack
cell
volum
admiss
parasit
count
moder
sever
malaria
group
drug
produc
rapid
parasit
clearanc
former
latter
find
suggest
either
reduc
splenic
clearanc
function
larger
biomass
sequest
parasit
sever
malaria
absorpt
disposit
indic
chloroquin
similar
uncompl
sever
pharmacokinet
factor
would
therefor
explain
differ
parasitis
erythrocyt
larg
ring
form
remov
circul
drug
treatment
fulli
understood
mechan
may
distinct
abil
antimalari
drug
inhibit
kill
matur
parasit
sequest
microcircul
vital
studi
done
chloroquin
highli
effect
treatment
falciparum
malaria
gambia
howev
resist
develop
rapidli
parasit
clearanc
measur
longer
rl
resist
seen
half
patient
admit
studi
site
unpublish
highgrad
resist
soon
preclud
use
chloroquin
sever
malaria
treatment
need
urgent
artemesinin
compound
promis
howev
evid
yet
save
live
quinin
chloroquin
given
appropri
dose
issu
resolv
satisfactorili
larg
compar
studi
mortal
endpoint
lymphocyt
sialaden
sj
ouml
gren
syndrom
associ
chronic
hepat
c
viru
liver
diseas
viral
infect
often
suggest
possibl
caus
sj
ouml
gren
syndrom
chronic
lymphocyt
sialaden
epsteinbarr
viru
found
salivari
gland
patient
condit
note
sj
ouml
gren
syndrom
sever
patient
infect
hepat
c
viru
hcv
viru
also
excret
saliva
set
prospect
studi
investig
associ
chronic
lymphocyt
sialaden
without
symptom
chronic
hcv
liver
diseas
histolog
appear
labial
salivari
gland
patient
proven
hcv
hepat
cirrhosi
compar
dead
control
histolog
chang
characterist
sj
ouml
gren
syndrom
significantli
common
hcvinfect
patient
compar
control
focal
lymphocyt
sialaden
characterist
sj
ouml
gren
syndrom
though
patient
xerostomia
none
complain
xerophthalmia
appear
common
patient
chronic
hcv
liver
diseas
associ
confirm
identif
underli
mechan
may
improv
understand
disord
sjogren
syndrom
gener
thought
autoimmun
diseas
associ
chronic
lymphocyt
infiltr
salivari
lacrim
autoantibodi
sometim
detect
serum
factor
might
trigger
focal
immun
reaction
remain
unknown
viral
infect
repeatedli
suggest
possibl
rat
coronaviru
infect
salivari
lacrim
gland
lead
chronic
sialadenodacryoaden
akin
sjogren
syndrom
epsteinbarr
viru
ebv
recent
found
salivari
gland
patient
sjogren
may
respons
mani
case
like
ebv
hepat
c
viru
hcv
excret
saliva
may
detect
patient
chronic
hcv
hepat
cirrhosi
hcv
infect
transmit
saliva
observ
sjogren
syndrom
patient
chronic
hcv
infect
wonder
whether
might
link
hcv
infect
salivari
gland
inflamm
set
prospect
studi
labial
salivari
gland
patient
chronic
hcv
hepat
cirrhosi
april
march
patient
nona
nonb
hepat
cirrhosi
refer
hepat
biopsi
enter
studi
antihcv
posit
firstgener
enzymelink
immunosorb
assay
elisa
chironortho
diagnost
raritan
new
jersey
usa
serum
sampl
retest
secondgener
antihcv
elisa
recombin
immunoblot
assay
riba
ortho
measur
antibodi
differ
viral
antigen
patient
remain
seroneg
exclud
patient
men
women
mean
age
rang
year
hcv
infect
consid
caus
chronic
liver
diseas
epidemiolog
histolog
data
tabl
caus
chronic
hepat
particularli
autoimmun
hepat
exclud
patient
antimitochondri
liverkidney
microsom
antibodi
smoothmuscl
antibodi
found
patient
titr
antinuclear
antibodi
found
indirect
immunofluoresc
rat
liver
kidney
section
patient
low
titr
tabl
alway
irregular
immunofluoresc
pattern
patient
subsequ
receiv
million
unit
ainterferon
thrice
weekli
transaminas
concentr
month
return
normal
patient
improv
still
rais
unchang
like
caus
hcv
infect
blood
transfus
mean
delay
se
year
transfus
biopsi
acupunctur
intraven
drug
inject
clear
risk
factor
could
identifi
tabl
show
activ
liver
diseas
characteris
knodel
score
patient
also
histolog
evid
cirrhosi
strike
steatosi
hepatocyt
larg
lymphocyt
nodul
consecut
patient
underw
necropsi
institut
period
use
control
histolog
examin
salivari
gland
secondarili
exclud
hcv
cirrhosi
autoimmun
cirrhosi
remain
control
studi
men
women
mean
age
year
rang
main
caus
death
stroke
cancer
alcohol
cirrhosi
cardiac
failur
pulmonari
embol
bacteri
infect
multipl
myeloma
main
associ
diseas
diabet
mellitu
hypertens
renal
failur
arter
hypothyroid
patient
hcv
infect
ask
directli
symptom
xerostomia
xerophthalmia
patient
complain
ocular
symptom
randomli
select
undergo
ophthalmolog
examin
includ
schirmer
tear
test
rosebeng
dye
test
labial
salivari
gland
sampl
normal
mucosa
accord
protocol
patient
control
sampl
similar
size
fix
boin
fluid
embed
paraffin
stain
haematoxylineosinsafranin
section
examin
pathologist
awar
origin
sampl
grade
accord
chisholm
mason
classif
section
patient
hcv
complain
xerostomia
symptom
sever
patient
complain
xerophthalmia
patient
randomli
assign
ophthalmolog
examin
posit
schirmer
test
also
posit
rosebeng
test
antinuclear
antibodi
titr
result
histolog
examin
labial
salivarygland
biopsi
shown
tabl
patient
chronic
hcv
liver
diseas
histolog
evid
sjogren
syndrom
compar
control
p
biopsi
result
control
grade
grade
grade
grade
grade
patient
labial
biopsi
grade
compar
labial
biopsi
grade
statist
signific
differ
regard
sex
age
mode
contamin
yglobulin
concentr
knodel
score
respons
interferon
tabl
patient
sjogren
syndrom
symptom
xerostomia
xerophthalmia
caus
lymphocyt
infiltr
destruct
lacrim
salivari
gland
diagnost
criteria
even
definit
condit
subject
much
debat
although
diagnosi
made
clinic
ground
alon
mani
wide
accept
histolog
appear
salivari
gland
use
guid
focu
lymphocyt
per
salivari
gland
section
diagnost
condit
biopsi
specimen
taken
normal
sensit
techniqu
reduc
biopsi
sampl
contain
less
salivari
gland
may
occur
advanc
stage
sialaden
extens
atrophi
fibrosi
labial
salivari
gland
author
suggest
patient
grade
lymphocyt
infiltr
extens
fibrosi
could
consid
sjogren
syndrom
criteria
patient
chronic
hcv
liver
diseas
would
qualifi
diagnosi
use
strict
criteria
statist
analysi
good
specif
chisholm
mason
find
grade
chang
among
control
nevertheless
found
minor
inflammatori
chang
common
older
peopl
especi
women
occasion
lymphocyt
foci
greenspan
et
aho
found
specimen
grade
chang
though
none
grade
unselect
necropsi
specimen
view
age
sex
distribut
patient
chronic
hcv
liver
diseas
compar
control
similar
sex
ratio
slightli
higher
mean
age
control
grade
sialaden
compar
hcv
infect
chronic
liver
diseasewhich
therefor
seem
predispos
focal
lymphocyt
sialaden
characterist
sjogren
syndrom
howev
patient
xerostomia
mild
none
complain
xerophthahnia
although
patient
examin
abnorm
schirmer
rosebeng
test
may
appropri
use
term
sicca
complex
chronic
lymphocyt
sialaden
instead
sjogren
syndrom
whatev
label
condit
well
known
chronic
autoimmun
liver
diseas
primari
biliari
cirrhosi
autoimmun
chronic
activ
hepat
cryptogen
even
use
addit
argument
support
autoimmun
pathogenesi
diseas
although
link
sjogren
syndrom
autoimmun
liver
diseas
proven
absenc
hcv
infect
clear
recent
patient
chronic
hcv
liver
diseas
thought
autoimmun
liver
diseas
occasion
coexist
sjogren
syndrom
patient
may
mislead
although
falseposit
result
antihcv
antibodi
report
autoimmun
liver
patient
confirm
antihcv
antibodi
riba
low
concentr
absenc
circul
autoantibodi
respons
interferon
support
diagnosi
chronic
hcv
liver
diseas
found
strike
associ
hcv
infect
sialaden
find
prove
direct
link
howev
sever
way
hcv
infect
might
caus
sialaden
smoothmuscl
liverkidney
microsom
antibodi
report
hcv
infect
interpret
secondari
immun
phenomena
antibodi
hostderiv
epitop
may
also
detect
earli
hcv
thu
autoimmun
reaction
may
explain
lymphocyt
infiltr
even
organ
infect
hcv
contain
target
epitop
hcv
genom
sequenc
may
also
found
mononuclear
cell
blood
infect
patient
c
brechot
person
commun
might
also
lead
abnorm
immun
respons
anoth
possibl
suggest
detect
ebv
salivari
gland
patient
sjogren
syndrom
hcv
found
saliva
infect
strikingli
similar
nodular
pattern
lymphocyt
infiltr
salivari
gland
liver
could
hcv
infect
salivari
gland
account
chronic
lymphocyt
sialaden
observ
identif
associ
nodular
chronic
lymphocyt
sialaden
chronic
hcv
liver
diseas
may
offer
new
insight
understand
condit
